Dark

Check out our Dark Pool Levels

ITCI
Intra-Cellular Therapies Inc.
stock NASDAQ

Inactive

Apr 1, 2025

131.87USD-0.038%(-0.05)16,062,974

Pre-market

0.00USD-100.000%(-131.92)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 7, 2022

04:01PM EST Intra-Cellular Therapies Announces Closing of $460 Million Public GlobeNewswire Inc

Jan 5, 2022

10:48AM EST Shares of biopharmaceutical company Intra-Cellular Therapies Inc. (ITCI) are up 4 percent on Wednesday's trading after the company announced the price of its underwritten public offering of 9.52 million shares at $42.00 per share. RTTNews

Jan 4, 2022

10:25PM EST Intra-Cellular Therapies Inc. (ITCI) said that it has priced its underwritten public offering of 9.52 million shares of its common stock at a public offering price of $42.00 per share. RTTNews

10:06PM EST Intra-Cellular Therapies Prices Public Offering of Common Stock GlobeNewswire Inc

08:11AM EST The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives Benzinga

06:07AM EST A Peek Into The Markets: US Stock Futures Up Ahead Of Manufacturing Report Benzinga

Jan 3, 2022

04:01PM EST Intra-Cellular Therapeutics Reports $400M Common Stock Offering Benzinga

04:01PM EST Intra-Cellular Therapies Announces Proposed Public Offering of GlobeNewswire Inc

08:00AM EST Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 am ET. GlobeNewswire Inc

Dec 21, 2021

07:05AM EST RBC Capital Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $55 Benzinga

Dec 20, 2021

10:36AM EST Analyst Ratings For Intra-Cellular Therapies Benzinga

10:16AM EST Intra-Cellular Therapies Shares Up 22%; Cannacord Raises Price Target To $88 Benzinga

09:21AM EST Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $59 Benzinga

07:25AM EST The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.10 A.M. ET). RTTNews

06:48AM EST Intra-Cellular Therapies Announces U.S. FDA Approval Of CAPLYTA For The Treatment Of Bipolar Depression in Adults Benzinga

06:47AM EST CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. GlobeNewswire Inc

04:52AM EST SVB Leerink Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $50 Benzinga

Dec 17, 2021

07:54AM EST The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx Benzinga

Dec 12, 2021

04:56PM EST The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More Benzinga

Dec 6, 2021

04:01PM EST Intra-Cellular Therapies Mourns the Passing of Director, Dr. GlobeNewswire Inc

Dec 2, 2021

12:02PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 10, 2021

11:50AM EST Looking Into Intra-Cellular Therapies's Return On Capital Employed Benzinga

08:50AM EST RBC Capital Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $50 Benzinga

Nov 9, 2021

11:42AM EST Intra-Cellular Therapies: Q3 Earnings Insights Benzinga

11:36AM EST Intra-Cellular Therapies Q3 EPS $(0.95) Misses $(0.92) Estimate, Sales $22.21M Beat $22.12M Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

07:30AM EST CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021. GlobeNewswire Inc

Nov 2, 2021

08:00AM EDT Intra-Cellular Therapies to Host Third Quarter 2021 Financial GlobeNewswire Inc

Oct 19, 2021

07:57AM EDT RBC Capital Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $48 Benzinga

Oct 18, 2021

08:00AM EDT Intra-Cellular Therapies Announces Amended Start Time to Virtual GlobeNewswire Inc

Oct 8, 2021

08:05AM EDT Intra-Cellular Therapies Will Host A Virtual Event To Discuss Co.'s Pipeline Wednesday, Oct. 20 From 12:30-3:30 p.m. EDT Benzinga

08:00AM EDT Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms GlobeNewswire Inc

Sep 27, 2021

07:33AM EDT Intra-Cellular Therapies Highlights Publication Of Lumateperone Pivotal Phase 3 Study In Bipolar Depression In The American Journal Of Psychiatry Benzinga

07:30AM EDT In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I or bipolar II disorder and a favorable safety and tolerability profile. These anti-depressant effects were statistically significant in both bipolar I and bipolar II disorder subgroup populations GlobeNewswire Inc

Sep 23, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 Benzinga

04:46AM EDT Needham Initiates Coverage On Intra-Cellular Therapies with Buy Rating, Announces Price Target of $55 Benzinga

Sep 22, 2021

08:00AM EDT Intra-Cellular Therapies to Present at the 2021 Cantor Virtual GlobeNewswire Inc

Sep 20, 2021

11:03AM EDT Looking Into Intra-Cellular Therapies's Return On Capital Employed Benzinga

08:30AM EDT Jefferies Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $70 Benzinga

07:37AM EDT Intra-Cellular Therapies Announces Publications Highlighting 'Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging' Benzinga

07:30AM EDT Results of Study ITI-214-104 show that lenrispodun, in a Phase 1/2a Study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms (Circulation: Heart Failure; Gilotra, et al, 2021) GlobeNewswire Inc

Aug 10, 2021

08:00AM EDT Intra-Cellular Therapies to Present at the Canaccord Genuity 41st GlobeNewswire Inc

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

07:52AM EDT Intra-Cellular Therapies: Q2 Earnings Insights Benzinga

07:35AM EDT Intra-Cellular Therapies Q2 EPS $(0.85) Misses $(0.80) Estimate, Sales $20.05M Beat $19.44M Estimate Benzinga

07:30AM EDT CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021. GlobeNewswire Inc

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 2, 2021

09:53AM EDT Intra-Cellular Therapies Sponsored Study Titled 'Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder' Posted To ClinicalTrials.Gov Site; Study Is Recruiting Benzinga

08:00AM EDT Intra-Cellular Therapies to Host Second Quarter 2021 Financial GlobeNewswire Inc

Jun 24, 2021

08:12AM EDT The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO Benzinga

Jun 23, 2021

10:48AM EDT Looking Into Intra-Cellular Therapies's Return On Capital Employed Benzinga

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

Jun 22, 2021

08:12AM EDT The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal Benzinga

Jun 16, 2021

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

Jun 11, 2021

08:05AM EDT The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts Benzinga

Jun 10, 2021

08:13AM EDT The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal Benzinga

Jun 8, 2021

09:17AM EDT The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex Benzinga

Jun 7, 2021

10:02AM EDT Looking Into Intra-Cellular Therapies's Return On Capital Employed Benzinga

08:09AM EDT Intra-Cellular Therapies Says Co's CAPLYTA Schizophrenia Safety And Tolerability Profile Published In The Journal 'International Clinical Psychopharmacology' Benzinga

08:00AM EDT Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg GlobeNewswire Inc

May 26, 2021

08:00AM EDT Intra-Cellular Therapies, Inc.(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at two upcoming investor conferences: GlobeNewswire Inc

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 10, 2021

08:05AM EDT Intra-Cellular Therapies Q1 Net Loss $52.7 Mln Vs Loss Of $47.4 Mln Last Year RTTNews

08:01AM EDT Recap: Intra-Cellular Therapies Q1 Earnings Benzinga

07:32AM EDT Intra-Cellular Therapies Q1 EPS $(0.65) Beats $(0.80) Estimate, Sales $15.88M Miss $16.50M Estimate Benzinga

07:30AM EDT CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for review by the FDA, with a PDUFA target action date of December 17, 2021. GlobeNewswire Inc

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 5, 2021

08:00AM EDT Intra-Cellular Therapies, Inc.(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at two upcoming investor conferences: GlobeNewswire Inc

May 4, 2021

08:00AM EDT Intra-Cellular Therapies to Host First Quarter 2021 Financial GlobeNewswire Inc

May 3, 2021

07:33AM EDT Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA sNDAs for the Treatment of Bipolar Depression Benzinga

07:30AM EDT Intra-Cellular Therapies Announces FDA Acceptance of GlobeNewswire Inc

Apr 22, 2021

07:30AM EDT Intra-Cellular Therapies Announces Investor Webcast and GlobeNewswire Inc

Apr 20, 2021

07:00AM EDT Intra-Cellular Therapies Announces Board of Director Nominations GlobeNewswire Inc

Apr 12, 2021

07:40AM EDT Intra-Cellular Therapies Presents Data On Antitumor Effects Of PDE1 Inhibition In A Preclinical Colorectal Cancer Model RTTNews

07:35AM EDT Intra-Cellular Therapies Highlights Poster Presentation Of PDE1 Inhibitor Program At American Association for Cancer Research Virtual Annual Meeting Benzinga

07:30AM EDT Our research has demonstrated that the phosphodiesterase type 1 (PDE1) enzyme modulates the immune system by reducing macrophage and microglial activity with demonstrated effects in neuroinflammatory conditions, cancer and cardiac diseases. GlobeNewswire Inc

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

08:02AM EST Intra-Cellular Therapies Q4 EPS $(0.76) Beats $(0.85) Estimate, Sales $12.45M Beat $11.84M Estimate Benzinga

07:30AM EST Successfully launched CAPLYTA (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19. GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 24, 2021

10:42AM EST Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes Benzinga

07:40AM EST Intra-Cellular Therapies Announces Addition Of ITI-1284 To Its Pipeline Benzinga

07:30AM EST ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particularly in elderly populations. GlobeNewswire Inc

Feb 23, 2021

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

Feb 22, 2021

01:15PM EST Intra-Cellular Therapies Files US Application For Expanded Use Of Lumateperone In Bipolar Settings Benzinga

08:03AM EST Intra-Cellular Therapies Applies For FDA Approval Of CAPLYTA For The Treatment Of Bipolar Depression Benzinga

08:00AM EST -- ITCI submits Supplemental New Drug Applications (sNDAs) for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults. -- If approved, CAPLYTA has the potential to treat the broadest range of patients with bipolar depression. GlobeNewswire Inc

Feb 19, 2021

08:00AM EST Intra-Cellular Therapies to Present at theSVB Leerink GlobeNewswire Inc

Feb 17, 2021

08:00AM EST Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 GlobeNewswire Inc

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Feb 4, 2021

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Jan 21, 2021

08:13AM EST Intra-Cellular Therapies Highlights CAPLYTA Open-Label Safety Switching Study In Patients With Schizophrenia Published In Journal, Schizophrenia Research Benzinga

08:00AM EST Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back to previous or another approved antipsychotic. GlobeNewswire Inc

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 13, 2021

07:25AM EST The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga

Jan 5, 2021

08:00AM EST Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 9:10 am ET. GlobeNewswire Inc

Dec 29, 2020

11:25AM EST Intra-Cellular Therapies shares were trading higher after the company announced the initiation of clinical trials of ITI-LLAI, for the treatment of schizophrenia, and ITI-333, for the treatment of opioid use disorder. Benzinga

08:17AM EST Intra-Cellular Therapies Begins Clinical Programs For ITI-LLAI And For ITI-333 RTTNews

08:07AM EST Intra-Cellular Therapies Announces Initiation Of Clinical Trials For ITI-LLAI Long-Acting Injectable Formulation Of Lumateperone For Treatment Of Schizophrenia And ITI-333, A Novel Treatment For Opioid Use Disorder Benzinga

08:00AM EST The Company continues expansion of its lumateperone programs with the advancement of a Long-Acting injectable formulation into clinical trials. GlobeNewswire Inc

Dec 10, 2020

07:11AM EST Goldman Sachs Initiates Coverage On Intra-Cellular Therapies with Buy Rating, Announces Price Target of $38 Benzinga

Dec 9, 2020

08:00AM EST Presentations highlight lumateperones broad antidepressant effects in patients with bipolar disorder and in patients with schizophrenia with co-morbid depression GlobeNewswire Inc

Nov 30, 2020

08:00AM EST Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual GlobeNewswire Inc

Nov 9, 2020

08:19AM EST Recap: Intra-Cellular Therapies Q3 Earnings Benzinga

07:39AM EST Intra-Cellular Therapies Q3 EPS $(0.79) Beats $(1.00) Estimate, Sales $7.37M Beat $5.86M Estimate Benzinga

07:30AM EST Positive topline results reported from Study 402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression. GlobeNewswire Inc

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 4, 2020

10:24AM EST Mid-Morning Market Update: Markets Open Higher; Performance Food Earnings Top Views Benzinga

08:00AM EST Intra-Cellular Therapies to Host Third Quarter 2020 Financial GlobeNewswire Inc

Nov 2, 2020

09:02AM EST BTIG Maintains Buy on Intra-Cellular Therapies, Lowers Price Target to $40 Benzinga

Oct 2, 2020

07:01AM EDT New Ventures Funds Rebrands as Scientia Ventures PR Newswire

Oct 1, 2020

04:39PM EDT Intra-Cellular Therapies Announces The Appointment Of Suresh Durgam As Chief Medical Officer Benzinga

04:30PM EDT Intra-Cellular Therapies Announces the Appointment of Dr. Suresh GlobeNewswire Inc

Sep 20, 2020

10:09AM EDT Notable Insider Buys of the Past Week: Nikola, Transdigm And More Benzinga

Sep 15, 2020

08:00AM EDT Intra-Cellular Therapies to Present at the Morgan Stanley 18th GlobeNewswire Inc

Sep 14, 2020

10:04AM EDT Intra-Cellular Therapies Option Alert: Oct 16 $35 Calls Sweep (8) near the Ask: 305 @ $0.901 vs 1558 OI; Earnings 11/3 Before Open [est] Ref=$29.08 Benzinga

08:00AM EDT Intra-Cellular Therapies to Present at the Cantor Virtual Global GlobeNewswire Inc

Sep 10, 2020

11:25PM EDT Intra-Cellular Therapies Prices Public Offering Of 11.67 Mln Shares At $30.00/shr RTTNews

08:30PM EDT Intra-Cellular Therapies Prices Public Offering of Common Stock GlobeNewswire Inc

01:22PM EDT Intra-Cellular Therapies shares are trading lower after the company announced a $350 million common stock offering. Benzinga

Sep 9, 2020

04:02PM EDT Intra-Cellular Therapies Announces Proposed Public Offering Priced At $350M Benzinga

04:01PM EDT Intra-Cellular Therapies Announces Proposed Public Offering of GlobeNewswire Inc

02:30PM EDT Mid-Afternoon Market Update: Nasdaq Surges 300 Points; Slack Shares Plunge Benzinga

12:19PM EDT Intra-Cellular Therapies Shares Quiet; JPM Raises Price Target From $47 To $54, Reiterates Market Outperform Benzinga

12:05PM EDT Mid-Day Market Update: Dow Jumps Over 500 Points; Trillium Therapeutics Shares Spike Higher Benzinga

10:24AM EDT Mid-Morning Market Update: Markets Open Higher; AstraZeneca Halts Coronavirus Vaccine Study Benzinga

10:05AM EDT Shares of Intra-Cellular Therapies, Inc. (ITCI) are currently surging over 60% on Wednesday morning after the biopharmaceutical company announced positive results from a late-stage study evaluating a therapy for bipolar depression. RTTNews

09:08AM EDT ROCE Insights For Intra-Cellular Therapies Benzinga

08:50AM EDT Shares of Intra-Cellular Therapies Inc. (ITCI) are rising over 82% in pre-market today, after the company reported positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. RTTNews

07:28AM EDT Intra-Cellular Therapies Announces Topline Results From Study 402 Evaluating Lumateperone; Lumateperone 42 mg Achieved Statistically Significant Results In Primary And Key Secondary Endpoints Benzinga

07:00AM EDT Lumateperone 42 mg achieved statistically significant results in primary and key secondary endpoints in Study 402. Company expects to submit supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) in late 2020 or early 2021. GlobeNewswire Inc

Aug 10, 2020

10:21AM EDT Shares of Intra-Cellular Therapies, Inc. (ITCI) are down more than 10% Monday morning on missing second-quarter results. RTTNews

07:57AM EDT Recap: Intra-Cellular Therapies Q2 Earnings Benzinga

07:43AM EDT Intra-Cellular Therapies Q2 EPS $(0.96) Misses $(0.91) Estimate, Sales $1.91M Miss $3.03M Estimate Benzinga

07:42AM EDT Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter ended June 30, 2020, and provided a corporate update. GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 4, 2020

08:00AM EDT Intra-Cellular Therapies to Host Second Quarter 2020 Financial GlobeNewswire Inc

Jul 29, 2020

11:05AM EDT Intra-Cellular Therapies Option Alert: Aug 21 $30 Calls at the Ask: 1000 @ $1.5 vs 14826 OI; Earnings 8/10 Before Open [est] Ref=$20.24 Benzinga

Share